Cross-country comparison in the evaluation of evolocumab by health technology assessment agencies in England, Canada, and Australia
Evolocumab is a proprotein convertase subtilisin/kexin type 9 inhibitor drug which has shown great treatment effects in the treatment of uncontrolled hypercholesterolemia, particularly elevated low-density lipoprotein cholesterol levels. Due to its significant costs, several health technology assess...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Wolters Kluwer Medknow Publications
2019-01-01
|
| Colección: | Heart and Mind |
| Materias: | |
| Acceso en línea: | http://www.heartmindjournal.org/article.asp?issn=2468-6476;year=2019;volume=3;issue=4;spage=140;epage=146;aulast=Varghese |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|